Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer
Conclusions The suggested upper threshold for the therapeutic window of everolimus Ctrough was 17.3 ng/mL. Pharmacokinetically guided dosing may improve the efficacy and safety of everolimus for mBC, warranting further investigation in a larger study.Clinical trial registry: Not applicable.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Study | Toxicology